A Phase 2 interventional study of bimagrumab and placebo in Muscle Wasting (Atrophy) After Hip Fracture Surgery, sponsored by Novartis Pharmaceuticals. Completed at 53 sites in 19 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2020-08-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Muscular Atrophy by Novartis — 1 open to participants now, 2 under way, 1 of them phase 3. Muscular Atrophy · Novartis.
Among the 13 studies in Muscular Atrophy by Novartis, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2014, is one of 4 in phase 2, and was the 3rd registered.
413 studies on the registry are indexed under Muscular Atrophy; 77 are open to participants now.
Browse Muscular Atrophy studies →1 of the 13 studies in Muscular Atrophy by Novartis is open now, in 1 country. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Brazil
Ages 0–100
By country, each count listing its studies:
Of the 52 Muscular Atrophy studies recruiting now, 25 (48%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6 · Phase 4 2
First in 2012; this study’s year is marked. 2 started in 2014.
This study's enrollment of 251 is above the median of 40 across 327 interventional studies indexed under Muscular Atrophy.
Median enrollment 112 across the 12 interventional studies, 50 across the 1 observational. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Muscular Atrophy by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have X-ray confirmed successful hip fracture repair; Must have completed surgical wound healing; Ability to walk a specified distance with or without a walking aid; Must weigh at least 35 kg.
Exclusion Criteria:
Must not have history of any other lower limb fractures in the past 6 months; Must not have certain cardiovascular conditions; Must not have a chronic active infection (e.g. , or C, etc); Must not have used high-dose medications for at least 3 months in the past year;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
Drug: bimagrumab
Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
Drug: bimagrumab
Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
Other: placebo
Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20
Drug: bimagrumab
Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
Also known as: BYM338
Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24
Mixed Model for Repeated Measures (MMRM) of change from baseline in total LBM (kg) by treatment and visit To assess dose-response relationship of bimagrumab and facilitate an adequate dose selection for future phase III studies, without the need for supportive data from another dose-response finding study, at least three doses were required, ranging from a non-effective or minimally effective dose to a dose where maximal efficacy is expected. Original study was initiated with only two doses of bimagrumab, therefore, a lower dose arm of 70mg has been added to this study with Amendment 2, changing the randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, bimagrumab 210mg, or bimagrumab 700mg. Since the 70mg dose was expected to show suboptimal efficacy and fewer patients were randomized to this group, it was used only for dose response modelling and not for hypothesis testing. Consequently, no efficacy evaluations for the bimagrumab 70mg Arm were performed
Time frame: baseline, weeks 12 and 24
Change From Baseline in Gait Speed at Week 24 (Meters/Sec)
Mixed Model for Repeated Measures (MMRM) of change from baseline in derived gait speed (m/sec) by treatment and visit To assess dose-response relationship of bimagrumab and facilitate an adequate dose selection for future phase III studies, without the need for supportive data from another dose-response finding study, at least 3 doses were required, ranging from a non-effective or minimally effective dose to a dose where maximal efficacy is expected. Original study was initiated with only two doses of bimagrumab, therefore, a lower dose arm of 70mg was added to this study with Amendment 2, changing the randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, bimagrumab 210mg, or bimagrumab 700mg. Since the 70mg dose was expected to show suboptimal efficacy and fewer patients were randomized to this group, it was used only for dose response modelling and not for hypothesis testing. Consequently, no efficacy evaluations for the bimagrumab 70mg Arm were performed
Time frame: Baseline, Week 24
Change From Baseline in Short Physical Performance Battery at Weeks 24
MMRM change from baseline in total score by treatment \& visit to Week 24 in physical performance measured by Short Physical Performance Battery (SPPB) that evaluates lower extremity function. Score range is 0 (worst performance) to 12 (best) to assess dose-response relationship of bimagrumab \& facilitate adequate dose selection for future phase III studies, without need for supportive data from another dose-response finding study, at least 3 doses were required, ranging from non- or minimally effective dose to a dose where maximal efficacy was expected. Original study was initiated with only 2 doses, therefore, lower 70mg arm was added to this study, changing randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, 210mg, or 700mg. Since 70mg dose was expected to show suboptimal efficacy, fewer patients were randomized to this group \& it was used only for dose response modelling \& not hypothesis testing. Consequently, no efficacy evaluation for 70mg were performed
Time frame: Week 24
Incidence of Falls up to Week 48
Group falls rate The frequency of having at least one fall up to Week 48 was summarized by treatment groups Incidence of falls was calculated for each arm up to Week 48. The ratio of these fall rates versus Placebo were calculated and presented as the Falls Rate Ratio. As mentioned in comment 5.1 above, the Falls Rate Ratio for Placebo does not apply because it would entail comparing the group to itself
Time frame: Up to Week 48
384 subjects were screened, and 252 subjects completed Screening period. One was lost to follow-up after screening and did not attend any visits for treatment epoch therefore, 251 were recruited to study. 2 subjects died during Screening epoch (1 was reported as discontinued and 1 was reported as a screen failure)
| Milestone | Bimagrumab 700 mg | Bimagrumab 210 mg | Bimagrumab 70 mg | Placebo |
|---|---|---|---|---|
| Started | 75 | 70 | 34 | 72 |
| Completed | 64 | 50 | 29 | 64 |
| Not completed | 11 | 20 | 5 | 8 |
| Withdrew: Technical problems | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 8 | 3 | 5 |
| Withdrew: Adverse event | 3 | 6 | 1 | 2 |
| Withdrew: Death | 0 | 3 | 1 | 0 |
| Withdrew: Non-compliance with treatment | 1 | 1 | 0 | 0 |
| Milestone | Bimagrumab 700 mg | Bimagrumab 210 mg | Bimagrumab 70 mg | Placebo |
|---|---|---|---|---|
| Started | 67 | 54 | 30 | 68 |
| Completed | 63 | 47 | 30 | 66 |
| Not completed | 4 | 7 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 4 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 1 |
Mixed Model for Repeated Measures (MMRM) of change from baseline in total LBM (kg) by treatment and visit To assess dose-response relationship of bimagrumab and facilitate an adequate dose selection for future phase III studies, without the need for supportive data from another dose-response finding study, at least three doses were required, ranging from a non-effective or minimally effective dose to a dose where maximal efficacy is expected. Original study was initiated with only two doses of bimagrumab, therefore, a lower dose arm of 70mg has been added to this study with Amendment 2, changing the randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, bimagrumab 210mg, or bimagrumab 700mg. Since the 70mg dose was expected to show suboptimal efficacy and fewer patients were randomized to this group, it was used only for dose response modelling and not for hypothesis testing. Consequently, no efficacy evaluations for the bimagrumab 70mg Arm were performed
| kg | Bimagrumab 700 mg | Bimagrumab 210 mg | Active Total Efficacy (AT:E) | Placebo |
|---|---|---|---|---|
| week 12 | 1.066 ± 0.0107 | 1.052 ± 0.0109 | 1.059 ± 0.0096 | 1.009 ± 0.0103 |
| week 24 | 1.064 ± 0.0113 | 1.042 ± 0.0115 | 1.053 ± 0.0101 | 0.996 ± 0.0109 |
Mixed Model for Repeated Measures (MMRM) of change from baseline in derived gait speed (m/sec) by treatment and visit To assess dose-response relationship of bimagrumab and facilitate an adequate dose selection for future phase III studies, without the need for supportive data from another dose-response finding study, at least 3 doses were required, ranging from a non-effective or minimally effective dose to a dose where maximal efficacy is expected. Original study was initiated with only two doses of bimagrumab, therefore, a lower dose arm of 70mg was added to this study with Amendment 2, changing the randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, bimagrumab 210mg, or bimagrumab 700mg. Since the 70mg dose was expected to show suboptimal efficacy and fewer patients were randomized to this group, it was used only for dose response modelling and not for hypothesis testing. Consequently, no efficacy evaluations for the bimagrumab 70mg Arm were performed
| meters per second | Bimagrumab 700 mg | Bimagrumab 210 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Gait Speed at Week 24 (Meters/Sec) | 0.268 ± 0.0599 | 0.350 ± 0.0617 | 0.339 ± 0.0607 |
MMRM change from baseline in total score by treatment \& visit to Week 24 in physical performance measured by Short Physical Performance Battery (SPPB) that evaluates lower extremity function. Score range is 0 (worst performance) to 12 (best) to assess dose-response relationship of bimagrumab \& facilitate adequate dose selection for future phase III studies, without need for supportive data from another dose-response finding study, at least 3 doses were required, ranging from non- or minimally effective dose to a dose where maximal efficacy was expected. Original study was initiated with only 2 doses, therefore, lower 70mg arm was added to this study, changing randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, 210mg, or 700mg. Since 70mg dose was expected to show suboptimal efficacy, fewer patients were randomized to this group \& it was used only for dose response modelling \& not hypothesis testing. Consequently, no efficacy evaluation for 70mg were performed
| scores on a scale | Bimagrumab 700 mg | Bimagrumab 210 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Short Physical Performance Battery at Weeks 24 | 2.331 ± 0.5436 | 3.535 ± 0.5623 | 2.702 ± 0.5516 |
Group falls rate The frequency of having at least one fall up to Week 48 was summarized by treatment groups Incidence of falls was calculated for each arm up to Week 48. The ratio of these fall rates versus Placebo were calculated and presented as the Falls Rate Ratio. As mentioned in comment 5.1 above, the Falls Rate Ratio for Placebo does not apply because it would entail comparing the group to itself
| Number of Falls per week | Bimagrumab 700 mg | Bimagrumab 210 mg | Bimagrumab 70mg | Placebo |
|---|---|---|---|---|
| Incidence of Falls up to Week 48 | 0.31 (0.14 to 0.70) | 0.45 (0.20 to 0.99) | 0.36 (0.13 to 0.97) | 0.29 (0.13 to 0.64) |
Collected over AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 48 weeks. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BYM338 700 mg | 1/75 (1.3%) | 15/75 (20%) | 47/75 (62.7%) |
| BYM338 210 mg | 3/69 (4.3%) | 17/69 (24.6%) | 34/69 (49.3%) |
| BYM338 70 mg | 1/34 (2.9%) | 9/34 (26.5%) | 15/34 (44.1%) |
| AT:S | 5/178 (2.8%) | 41/178 (23%) | 96/178 (53.9%) |
| Placebo | 1/72 (1.4%) | 9/72 (12.5%) | 30/72 (41.7%) |
| Event | BYM338 700 mg | BYM338 210 mg | BYM338 70 mg | AT:S | Placebo |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/75 | 0/69 | 1/34 | 1/178 | 0/72 |
| Atrial fibrillationCardiac disorders | 1/75 | 1/69 | 1/34 | 3/178 | 0/72 |
| Cardiac failureCardiac disorders | 0/75 | 0/69 | 1/34 | 1/178 | 0/72 |
| Retinal haemorrhageEye disorders | 0/75 | 0/69 | 1/34 | 1/178 | 0/72 |
| HaematocheziaGastrointestinal disorders | 0/75 | 0/69 | 1/34 | 1/178 | 0/72 |
| Oedema peripheralGeneral disorders | 0/75 | 0/69 | 1/34 | 1/178 | 0/72 |
| BronchitisInfections and infestations | 1/75 | 1/69 | 1/34 | 3/178 | 0/72 |
| PneumoniaInfections and infestations | 0/75 | 1/69 | 1/34 | 2/178 | 1/72 |
| Urinary tract infectionInfections and infestations | 0/75 | 0/69 | 1/34 | 1/178 | 0/72 |
| UrosepsisInfections and infestations | 0/75 | 0/69 | 1/34 | 1/178 | 0/72 |
| Event | BYM338 700 mg | BYM338 210 mg | BYM338 70 mg | AT:S | Placebo |
|---|---|---|---|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 12/75 | 17/69 | 2/34 | 31/178 | 6/72 |
| FallInjury, poisoning and procedural complications | 14/75 | 12/69 | 6/34 | 32/178 | 13/72 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/75 | 6/69 | 5/34 | 19/178 | 5/72 |
| Oedema peripheralGeneral disorders | 9/75 | 3/69 | 1/34 | 13/178 | 4/72 |
| Urinary tract infectionInfections and infestations | 8/75 | 3/69 | 2/34 | 13/178 | 2/72 |
| DiarrhoeaGastrointestinal disorders | 7/75 | 4/69 | 0/34 | 11/178 | 1/72 |
| Back painMusculoskeletal and connective tissue disorders | 4/75 | 5/69 | 1/34 | 10/178 | 2/72 |
| ContusionInjury, poisoning and procedural complications | 3/75 | 1/69 | 0/34 | 4/178 | 5/72 |
| NasopharyngitisInfections and infestations | 5/75 | 1/69 | 2/34 | 8/178 | 2/72 |
| BronchitisInfections and infestations | 0/75 | 1/69 | 2/34 | 3/178 | 1/72 |
The Full Analysis Set (FAS) used for all efficacy analyses consists of all randomized patients who received at least one dose of treatment after randomization and had at least one post-dose efficacy assessment. Patients who were randomized in error were excluded. Patients were analyzed according to treatment they were assigned to at randomization.
| Age, Continuous(years) | Bimagrumab 700 mg | Bimagrumab 210 mg | Bimagrumab 70 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 76.1 ± 8.58 | 74.8 ± 8.94 | 76.1 ± 8.59 | 76.4 ± 7.88 | 75.8 ± 8.46 |
| Age, Customized(Participants) | Bimagrumab 700 mg | Bimagrumab 210 mg | Bimagrumab 70 mg | Placebo | Total |
|---|---|---|---|---|---|
| < 65 years | 9 | 9 | 4 | 3 | 25 |
| 65 - 74 years | 22 | 23 | 10 | 27 | 82 |
| 75 - 84 years | 30 | 26 | 16 | 32 | 104 |
| =>85 years | 14 | 11 | 4 | 10 | 39 |
| Sex: Female, Male(Participants) | Bimagrumab 700 mg | Bimagrumab 210 mg | Bimagrumab 70 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 54 | 48 | 21 | 53 | 176 |
| Male | 21 | 21 | 13 | 19 | 74 |
| Race/Ethnicity, Customized(Participants) | Bimagrumab 700 mg | Bimagrumab 210 mg | Bimagrumab 70 mg | Placebo | Total |
|---|---|---|---|---|---|
| Caucasian | 57 | 58 | 26 | 53 | 194 |
| Black | 0 | 0 | 0 | 0 | 0 |
| Asian | 13 | 8 | 6 | 17 | 44 |
| Other | 4 | 3 | 2 | 2 | 11 |
| Native American | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Sep 2014 to primary completion in May 2018, 43 months.
Results were first posted in Aug 2020, 2 years 3 months after primary completion. A results delay was requested in Oct 2018.
Of 19 phase 2 interventional studies under Muscular Atrophy, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 43. This study's 43 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab